Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) announced that its CEO, Rainer M. Blair, will present at the Cowen Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via a live webcast on www.danaher.com. Danaher is a global leader in science and technology, focused on improving quality of life and solving complex challenges across health care, environmental, and applied markets. With over 80,000 associates, Danaher upholds a strong operational culture through its Danaher Business System.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on April 29, 2022, to shareholders on record by March 25, 2022. Additionally, dividends for preferred stocks include $11.875 for its 4.75% Series A and $12.50 for its 5.00% Series B, both payable on April 15, 2022, to shareholders on record by March 31, 2022. This indicates continued shareholder returns and reflects the company’s confidence in its financial health.
Danaher Corporation (NYSE: DHR) announced strong financial results for Q4 and full year 2021. Q4 net earnings reached $1.8 billion, or $2.39 per share, a 44% increase year-over-year, with revenues of $8.1 billion, up 20.5%. Full year net earnings were $6.3 billion ($8.50 per share), a 74% rise, while revenues increased 32% to $29.5 billion. Operating cash flow rose 34.5% to $8.4 billion. CEO Rainer M. Blair highlighted a transformative year with strategic acquisitions totaling $11 billion and a strong foundation for future growth. The company projects high-single digit core revenue growth for 2022.
Pall Corporation, a subsidiary of Danaher, unveiled the Supralon hydraulic and lube oil filter element range on January 11, 2022. This product upgrade enhances existing filter lines, employing stress-resistant technology for better equipment protection. It promises reduced energy costs and lower maintenance expenses, thereby decreasing total filtration costs. Supralon filters match the form and function of previous models and can retrofit into existing systems to improve fluid cleanliness. The older filter models will be phased out in the coming months.
Danaher Corporation (DHR) announced its CEO, Rainer M. Blair, will discuss the company's strong fourth quarter 2021 results at the J.P. Morgan Healthcare Conference. Core revenue growth is expected to exceed prior guidance, with estimated revenues increasing by high-teens to low-twenties percent year-over-year. This growth is driven by exceptional performance in Life Sciences and Diagnostics, alongside a notable 10% rise in core business. The quarterly earnings call is set for January 27, 2022, to provide further insights.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will be webcast live and archived on Danaher's website.
Danaher is a global science and technology innovator focused on solving complex challenges in the healthcare, environmental, and applied end-markets. With about 69,000 associates across more than 20 operating companies, Danaher aims to improve quality of life worldwide.
Danaher Corporation (NYSE: DHR) has announced its quarterly earnings conference call for Q4 2021, scheduled on January 27, 2022, at 8:00 a.m. ET. The call will last around 1 hour and will be accessible via a live webcast on Danaher’s website under the 'Investors' section. A replay will be available after the event. Interested parties can join the call by dialing 800-895-3361 (U.S.) or +1 785-424-1062 (internationally) before the start time. The earnings press release and related materials will be posted online at 6:00 a.m. ET on the same day.
Danaher Corporation (NYSE: DHR) has announced a regular quarterly cash dividend of $0.21 per share on common stock, payable on January 28, 2022, to shareholders of record on December 30, 2021. Additionally, the Board approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Preferred Stock and $12.50 per share of its 5.00% Series B Preferred Stock, both payable on January 15, 2022, to holders of record on December 31, 2021.
Danaher Corporation (NYSE: DHR) has priced an offering of $1 billion in 2.800% senior notes due 2051, with an offering price set at 99.396% of the principal amount. The expected net proceeds are approximately $984 million, intended for redeeming all outstanding 2.500% senior notes due 2025, refinancing debt, working capital, and other corporate purposes. The offering is anticipated to close on December 10, 2021, subject to customary conditions. This move is part of Danaher's strategy to manage its debt efficiently.
IDBS, a Danaher operating company, launched Polar Insight, enhancing its BioPharma Lifecycle Management (BPLM) platform with advanced data analytics and visualization tools. This innovation replaces outdated manual processes, allowing for integrated digital workflows that streamline data handling from development to manufacturing. The new capabilities aim to accelerate innovation and regulatory filings, enabling clients to deliver vaccines and therapies more efficiently. The first dashboards will be available in Q1 2022.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
